All News
Filter News
Found 597 articles
-
Speculation Heats Up on Biogen as an Acquisition Target or Starting a Buying Spree
7/26/2016
-
Biogen CEO Steps Down Amid Stellar Q2 Financials, Hunt for New Leader Begins
7/22/2016
-
Evaluation: 7 Biopharma Companies’ Market Value Based on Pipelines
7/14/2016
-
4 High-Quality Biotechs Trading Like Risky Startups
7/12/2016
-
Biogen's $8 Billion Market Cap Drop Makes Thermo Fisher Scientific the New King in Massachusetts, But GE Corporation’s Coming to Town
6/10/2016
-
Amid Plunging Stocks and Failed Trials, Biogen’s CIO Quietly Leaves Company
6/10/2016
-
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted Into European Medicines Agency’s PRIME Program
6/1/2016
-
M&A Targets Pfizer and Others Could be Eyeballing
5/24/2016
-
3 Stocks with Moonshot Potential that are Safer Buys than bluebird bio
5/4/2016
-
Biogen Poaches Star Pfizer Scientist as New R&D Chief
4/29/2016
-
While Exploring Sale of Its Hemophilia Unit, Some Speculate Biogen Might be Prepping to Buy or be Acquired
4/13/2016
-
A Day After The Pfizer-Allergan Deal Dies, Allergan Inks Potential $3.3 Billion Alzheimer’s Deal with Heptares
4/11/2016
-
Nixed Pfallergan Deal Has Investors Wondering if Allergan Might Target Biogen
4/7/2016
-
Why SoCal's Acadia May Be a Perfect Takeover Target for Biogen
4/5/2016
-
Bay Area's XenoPort Snags Psoriasis and MS Deal Worth $490 Million+ from Dr. Reddy's Laboratories Ltd.
3/28/2016
-
Bay State's FORUM Pharma Lays Off 89 After Two Failed Clinical Trials
3/28/2016
-
TauRx Pharma Co-Founder's 30-Year Alzheimer's Quest May Bear Fruit in July
3/21/2016
-
BioPharm Executive: What Gets This Market Back on Track?
2/24/2016
-
Three Dinged Biopharmas that Could Make a Fierce Comeback
2/17/2016
-
Biogen Points Out Three New Risk Factors For 2016 in SEC Filing, Report Shows
2/9/2016